New therapeutic agent against arterial thrombosis

An iridium(III)-derived organometallic compound

Chih Wei Hsia, Marappan Velusamy, Jeng Ting Tsao, Chih Hsuan Hsia, Duen Suey Chou, Thanasekaran Jayakumar, Lin Wen Lee, Jiun Yi Li, Joen Rong Sheu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Platelet activation plays a major role in cardio and cerebrovascular diseases, and cancer progression. Disruption of platelet activation represents an attractive therapeutic target for reducing the bidirectional cross talk between platelets and tumor cells. Platinum (Pt) compounds have been used for treating cancer. Hence, replacing Pt with iridium (Ir) is considered a potential alternative. We recently developed an Ir(III)-derived complex, [Ir(Cp*)1-(2-pyridyl)-3-(2-hydroxyphenyl)imidazo[1,5-a]pyridine Cl]BF4 (Ir-11), which exhibited strong antiplatelet activity; hence, we assessed the therapeutic potential of Ir-11 against arterial thrombosis. In collagen-activated platelets, Ir-11 inhibited platelet aggregation, adenosine triphosphate (ATP) release, intracellular Ca2+ mobilization, P-selectin expression, and OH·formation, as well as the phosphorylation of phospholipase Cγ2 (PLCγ2), protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt. Neither the adenylate cyclase inhibitor nor the guanylate cyclase inhibitor reversed the Ir-11-mediated antiplatelet effects. In experimental mice, Ir-11 prolonged the bleeding time and reduced mortality associated with acute pulmonary thromboembolism. Ir-11 plays a crucial role by inhibiting platelet activation through the inhibition of the PLCγ2-PKC cascade, and the subsequent suppression of Akt and MAPK activation, ultimately inhibiting platelet aggregation. Therefore, Ir-11 can be considered a new therapeutic agent against either arterial thrombosis or the bidirectional cross talk between platelets and tumor cells.

Original languageEnglish
Article number2616
JournalInternational Journal of Molecular Sciences
Volume18
Issue number12
DOIs
Publication statusPublished - Dec 5 2017

Fingerprint

Organometallic Compounds
thrombosis
Iridium
organometallic compounds
Organometallics
iridium
Thrombosis
Platelets
platelets
Platelet Activation
Chemical activation
Therapeutics
activation
proteins
Proteins
Blood Platelets
Phospholipases
Mitogen-Activated Protein Kinases
Platelet Aggregation
inhibitors

Keywords

  • Bleeding time
  • Ir(III)-derived complex
  • OH· free radical
  • Platelet activation
  • Protein kinases
  • Pulmonary thromboembolism

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

New therapeutic agent against arterial thrombosis : An iridium(III)-derived organometallic compound. / Hsia, Chih Wei; Velusamy, Marappan; Tsao, Jeng Ting; Hsia, Chih Hsuan; Chou, Duen Suey; Jayakumar, Thanasekaran; Lee, Lin Wen; Li, Jiun Yi; Sheu, Joen Rong.

In: International Journal of Molecular Sciences, Vol. 18, No. 12, 2616, 05.12.2017.

Research output: Contribution to journalArticle

Hsia, Chih Wei ; Velusamy, Marappan ; Tsao, Jeng Ting ; Hsia, Chih Hsuan ; Chou, Duen Suey ; Jayakumar, Thanasekaran ; Lee, Lin Wen ; Li, Jiun Yi ; Sheu, Joen Rong. / New therapeutic agent against arterial thrombosis : An iridium(III)-derived organometallic compound. In: International Journal of Molecular Sciences. 2017 ; Vol. 18, No. 12.
@article{d2f63b8d88274a8198babd97790947fa,
title = "New therapeutic agent against arterial thrombosis: An iridium(III)-derived organometallic compound",
abstract = "Platelet activation plays a major role in cardio and cerebrovascular diseases, and cancer progression. Disruption of platelet activation represents an attractive therapeutic target for reducing the bidirectional cross talk between platelets and tumor cells. Platinum (Pt) compounds have been used for treating cancer. Hence, replacing Pt with iridium (Ir) is considered a potential alternative. We recently developed an Ir(III)-derived complex, [Ir(Cp*)1-(2-pyridyl)-3-(2-hydroxyphenyl)imidazo[1,5-a]pyridine Cl]BF4 (Ir-11), which exhibited strong antiplatelet activity; hence, we assessed the therapeutic potential of Ir-11 against arterial thrombosis. In collagen-activated platelets, Ir-11 inhibited platelet aggregation, adenosine triphosphate (ATP) release, intracellular Ca2+ mobilization, P-selectin expression, and OH·formation, as well as the phosphorylation of phospholipase Cγ2 (PLCγ2), protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt. Neither the adenylate cyclase inhibitor nor the guanylate cyclase inhibitor reversed the Ir-11-mediated antiplatelet effects. In experimental mice, Ir-11 prolonged the bleeding time and reduced mortality associated with acute pulmonary thromboembolism. Ir-11 plays a crucial role by inhibiting platelet activation through the inhibition of the PLCγ2-PKC cascade, and the subsequent suppression of Akt and MAPK activation, ultimately inhibiting platelet aggregation. Therefore, Ir-11 can be considered a new therapeutic agent against either arterial thrombosis or the bidirectional cross talk between platelets and tumor cells.",
keywords = "Bleeding time, Ir(III)-derived complex, OH· free radical, Platelet activation, Protein kinases, Pulmonary thromboembolism",
author = "Hsia, {Chih Wei} and Marappan Velusamy and Tsao, {Jeng Ting} and Hsia, {Chih Hsuan} and Chou, {Duen Suey} and Thanasekaran Jayakumar and Lee, {Lin Wen} and Li, {Jiun Yi} and Sheu, {Joen Rong}",
year = "2017",
month = "12",
day = "5",
doi = "10.3390/ijms18122616",
language = "English",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "12",

}

TY - JOUR

T1 - New therapeutic agent against arterial thrombosis

T2 - An iridium(III)-derived organometallic compound

AU - Hsia, Chih Wei

AU - Velusamy, Marappan

AU - Tsao, Jeng Ting

AU - Hsia, Chih Hsuan

AU - Chou, Duen Suey

AU - Jayakumar, Thanasekaran

AU - Lee, Lin Wen

AU - Li, Jiun Yi

AU - Sheu, Joen Rong

PY - 2017/12/5

Y1 - 2017/12/5

N2 - Platelet activation plays a major role in cardio and cerebrovascular diseases, and cancer progression. Disruption of platelet activation represents an attractive therapeutic target for reducing the bidirectional cross talk between platelets and tumor cells. Platinum (Pt) compounds have been used for treating cancer. Hence, replacing Pt with iridium (Ir) is considered a potential alternative. We recently developed an Ir(III)-derived complex, [Ir(Cp*)1-(2-pyridyl)-3-(2-hydroxyphenyl)imidazo[1,5-a]pyridine Cl]BF4 (Ir-11), which exhibited strong antiplatelet activity; hence, we assessed the therapeutic potential of Ir-11 against arterial thrombosis. In collagen-activated platelets, Ir-11 inhibited platelet aggregation, adenosine triphosphate (ATP) release, intracellular Ca2+ mobilization, P-selectin expression, and OH·formation, as well as the phosphorylation of phospholipase Cγ2 (PLCγ2), protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt. Neither the adenylate cyclase inhibitor nor the guanylate cyclase inhibitor reversed the Ir-11-mediated antiplatelet effects. In experimental mice, Ir-11 prolonged the bleeding time and reduced mortality associated with acute pulmonary thromboembolism. Ir-11 plays a crucial role by inhibiting platelet activation through the inhibition of the PLCγ2-PKC cascade, and the subsequent suppression of Akt and MAPK activation, ultimately inhibiting platelet aggregation. Therefore, Ir-11 can be considered a new therapeutic agent against either arterial thrombosis or the bidirectional cross talk between platelets and tumor cells.

AB - Platelet activation plays a major role in cardio and cerebrovascular diseases, and cancer progression. Disruption of platelet activation represents an attractive therapeutic target for reducing the bidirectional cross talk between platelets and tumor cells. Platinum (Pt) compounds have been used for treating cancer. Hence, replacing Pt with iridium (Ir) is considered a potential alternative. We recently developed an Ir(III)-derived complex, [Ir(Cp*)1-(2-pyridyl)-3-(2-hydroxyphenyl)imidazo[1,5-a]pyridine Cl]BF4 (Ir-11), which exhibited strong antiplatelet activity; hence, we assessed the therapeutic potential of Ir-11 against arterial thrombosis. In collagen-activated platelets, Ir-11 inhibited platelet aggregation, adenosine triphosphate (ATP) release, intracellular Ca2+ mobilization, P-selectin expression, and OH·formation, as well as the phosphorylation of phospholipase Cγ2 (PLCγ2), protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt. Neither the adenylate cyclase inhibitor nor the guanylate cyclase inhibitor reversed the Ir-11-mediated antiplatelet effects. In experimental mice, Ir-11 prolonged the bleeding time and reduced mortality associated with acute pulmonary thromboembolism. Ir-11 plays a crucial role by inhibiting platelet activation through the inhibition of the PLCγ2-PKC cascade, and the subsequent suppression of Akt and MAPK activation, ultimately inhibiting platelet aggregation. Therefore, Ir-11 can be considered a new therapeutic agent against either arterial thrombosis or the bidirectional cross talk between platelets and tumor cells.

KW - Bleeding time

KW - Ir(III)-derived complex

KW - OH· free radical

KW - Platelet activation

KW - Protein kinases

KW - Pulmonary thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85037337475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037337475&partnerID=8YFLogxK

U2 - 10.3390/ijms18122616

DO - 10.3390/ijms18122616

M3 - Article

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

M1 - 2616

ER -